HRP20210523T1 - Pripravci i postupci za liofilne oblike nanočestica - Google Patents

Pripravci i postupci za liofilne oblike nanočestica Download PDF

Info

Publication number
HRP20210523T1
HRP20210523T1 HRP20210523TT HRP20210523T HRP20210523T1 HR P20210523 T1 HRP20210523 T1 HR P20210523T1 HR P20210523T T HRP20210523T T HR P20210523TT HR P20210523 T HRP20210523 T HR P20210523T HR P20210523 T1 HRP20210523 T1 HR P20210523T1
Authority
HR
Croatia
Prior art keywords
cholesteryl
compound
hydroxyalkyl
cyclodextrin
nucleic acid
Prior art date
Application number
HRP20210523TT
Other languages
English (en)
Croatian (hr)
Inventor
Wenbin Ying
Roger Adami
Yuwei Wang
Haiqing Yin
Liping Wang
Dong Liu
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of HRP20210523T1 publication Critical patent/HRP20210523T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20210523TT 2015-07-22 2016-07-22 Pripravci i postupci za liofilne oblike nanočestica HRP20210523T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms
EP16828602.9A EP3324932B1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (1)

Publication Number Publication Date
HRP20210523T1 true HRP20210523T1 (hr) 2021-05-14

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210523TT HRP20210523T1 (hr) 2015-07-22 2016-07-22 Pripravci i postupci za liofilne oblike nanočestica

Country Status (23)

Country Link
US (3) US10300018B2 (cg-RX-API-DMAC7.html)
EP (1) EP3324932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716928B1 (cg-RX-API-DMAC7.html)
CN (2) CN113679689B (cg-RX-API-DMAC7.html)
AU (1) AU2016297153B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992849C (cg-RX-API-DMAC7.html)
CY (1) CY1123984T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324932T3 (cg-RX-API-DMAC7.html)
EA (1) EA035761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2862191T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053990T2 (cg-RX-API-DMAC7.html)
IL (2) IL288342B2 (cg-RX-API-DMAC7.html)
LT (1) LT3324932T (cg-RX-API-DMAC7.html)
MX (1) MX373982B (cg-RX-API-DMAC7.html)
PL (1) PL3324932T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324932T (cg-RX-API-DMAC7.html)
RS (1) RS61607B1 (cg-RX-API-DMAC7.html)
SI (1) SI3324932T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI732773B (cg-RX-API-DMAC7.html)
WO (1) WO2017015552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms
CA3085694A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
AU2019347774A1 (en) 2018-09-28 2021-03-25 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
JP7597334B2 (ja) * 2019-09-26 2024-12-10 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
AU2021228236A1 (en) * 2020-02-28 2022-10-06 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
WO2021216541A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL300519A (en) * 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method for lyophilization of lipid nanoparticles
WO2022071582A1 (ja) 2020-10-02 2022-04-07 国立大学法人北海道大学 脂質ナノ粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2004251680B2 (en) * 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
US20060110441A1 (en) 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 C70含有リポソームおよびその製造方法、並びにその利用
EP2509634B1 (en) * 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2648753C2 (ru) 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3673898A1 (en) 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
KR102123129B1 (ko) 2012-03-28 2020-06-15 디스커버리 라보라토리스, 인크. 합성 리포솜 폐 계면활성제의 동결건조
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms

Also Published As

Publication number Publication date
IL257029A (en) 2018-03-29
US20190231695A1 (en) 2019-08-01
PT3324932T (pt) 2021-04-06
AU2016297153A1 (en) 2018-03-01
CN108024957B (zh) 2021-08-24
US20170020819A1 (en) 2017-01-26
ES2862191T3 (es) 2021-10-07
KR102716928B1 (ko) 2024-10-11
US10300018B2 (en) 2019-05-28
EA201890367A1 (ru) 2018-06-29
EP3324932B1 (en) 2021-03-10
RS61607B1 (sr) 2021-04-29
JP6875373B2 (ja) 2021-05-26
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
JP2021119161A (ja) 2021-08-12
LT3324932T (lt) 2021-04-26
IL288342B2 (en) 2024-02-01
CY1123984T1 (el) 2022-05-27
SI3324932T1 (sl) 2021-07-30
MX373982B (es) 2020-07-15
TWI732773B (zh) 2021-07-11
JP2018521083A (ja) 2018-08-02
IL288342A (en) 2022-01-01
EP3324932A1 (en) 2018-05-30
SMT202100196T1 (it) 2021-05-07
WO2017015552A1 (en) 2017-01-26
EA035761B1 (ru) 2020-08-06
US12311055B2 (en) 2025-05-27
US11737982B2 (en) 2023-08-29
US20240000710A1 (en) 2024-01-04
PL3324932T3 (pl) 2021-07-05
IL288342B1 (en) 2023-10-01
CA2992849C (en) 2023-06-13
AU2016297153B2 (en) 2021-02-25
DK3324932T3 (da) 2021-04-06
EP3324932A4 (en) 2019-03-06
HUE053990T2 (hu) 2021-08-30
TW201717914A (zh) 2017-06-01
CN113679689B (zh) 2023-09-01
KR20180030698A (ko) 2018-03-23
JP7268079B2 (ja) 2023-05-02
CN108024957A (zh) 2018-05-11
CA2992849A1 (en) 2017-01-26
BR112018001178A2 (pt) 2018-09-11
CN113679689A (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
HRP20210523T1 (hr) Pripravci i postupci za liofilne oblike nanočestica
Loftsson et al. Self-association of cyclodextrins and cyclodextrin complexes in aqueous solutions
JP2018521083A5 (cg-RX-API-DMAC7.html)
Cherukuri et al. Formulation and evaluation of transdermal drug delivery of topiramate
Tang et al. Mesalazine/hydroxypropyl-β-cyclodextrin/chitosan nanoparticles with sustained release and enhanced anti-inflammation activity
Zhao et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials
Jana et al. Carbopol gel containing chitosan-egg albumin nanoparticles for transdermal aceclofenac delivery
Sajomsang et al. Water-soluble β-cyclodextrin grafted with chitosan and its inclusion complex as a mucoadhesive eugenol carrier
Piazzini et al. Solid lipid nanoparticles and chitosan-coated solid lipid nanoparticles as promising tool for silybin delivery: formulation, characterization, and in vitro evaluation
Wang et al. A comparison between conventional liposome and drug-cyclodextrin complex in liposome system
Plazzo et al. Uptake of a fluorescent methyl-β-cyclodextrin via clathrin-dependent endocytosis
Réti-Nagy et al. Endocytosis of fluorescent cyclodextrins by intestinal Caco-2 cells and its role in paclitaxel drug delivery
Malatesta et al. Internalized chitosan nanoparticles persist for long time in cultured cells
JP6538031B2 (ja) 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療
Cojocariu et al. In vitro drug release from chitosan/Cloisite 15A hydrogels
JP2014101382A5 (cg-RX-API-DMAC7.html)
HRP20220932T1 (hr) Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid
Patel et al. Improved transnasal transport and brain uptake of tizanidine HCl-loaded thiolated chitosan nanoparticles for alleviation of pain
Li et al. A macromolecular prodrug strategy for combinatorial drug delivery
Carvalho et al. Inclusion complex between β-cyclodextrin and hecogenin acetate produces superior analgesic effect in animal models for orofacial pain
CA2939261A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
Soltani et al. Evaluation of the hydatid cyst membrane permeability of albendazole and albendazole sulfoxide-loaded solid lipid nanoparticles
JP2019504056A5 (cg-RX-API-DMAC7.html)
Sripetch et al. Cyclodextrins and drug membrane permeation: thermodynamic considerations
Kwon et al. In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl β-cyclodextrin/minoxidil complex